Atherion Bioresearch Announces Partnership with Voxeleron

DUBLIN, Ohio - Oct. 9, 2023 - PRLog -- DUBLIN, Ohio—Atherion Bioresearch, Inc. ("Atherion" or the "Company"), a full-service Clinical Research Organization ("CRO") company established by experienced drug development professionals and focused on helping its partners advance their pipelines, today announced the signing of a collaborative agreement with Voxeleron, LLC. ("Voxeleron"), the leader in ophthalmic imaging analysis and ophthalmic clinical trial management solutions. Through this agreement, the companies are able to offer an expanded suite of services to potential sponsors.

Atherion provides a wide array of drug development services and is differentiated from other CROs by its high level of engagement and industry experience. Atherion's founding members are drug development professionals who have worked on the sponsor side to successfully advance drugs and complete trials and who have both private and public pharmaceutical/biotechnology experience. Atherion's team knows the common pitfalls of outsourcing to CROs and strives instead to be a true partner in diagnostic and therapeutic pipeline advancement.

Voxeleron leadership brings decades of experience in computer vision and image analysis to imaging in ophthalmology, particularly for optical coherence tomography ("OCT"). Orion™, Voxeleron's ophthalmic image analysis software, enables reading of images and data from the entire spectrum of devices,  allowing readers to attain best-in-class segmentation with proven, AI-enhanced analysis, and reduces read times through automated measurements using intuitive interfaces. Orion's advanced analysis tools are fully automated and entirely platform independent – truly vendor neutral – and processes data from all major OCT scanners in any of their formats. It also seamlessly interfaces with iNebula™, the company's complete, cloud-based clinical trial data platform.

The combination of the experience and expertise of these two companies brings together a powerful platform of services to help sponsors with their drug development needs.

Michael Rosol, PhD, Chief Executive Officer of Atherion, said, "I am pleased to announce this agreement with Voxeleron that will help amplify the reach and accelerate the growth of both of our companies." Dr. Rosol continued, "Atherion has the experience in clinical trial operations and strategy and Voxeleron brings to the table deep expertise in ophthalmic clinical image management and image analysis software. Together our two companies can function as a full-service ophthalmic imaging CRO in addition to our other capabilities in clinical development and imaging software solutions."

Jonathan Oakley, Chief Scientific Officer of Voxeleron, said, "We are very excited to be working with Atherion.  A clinical trial has so many moving parts, it is almost impossible to be the best at them all.  This partnership leverages our abilities in a very complete and resonant way to give sponsors an exceptionally strong option for managing their trials."

Learn more at: https://www.atherion-bioresearch.com/ and https://voxeleron.com/